TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9537491

Group type: EXPERIMENTAL
Intervention: Neonatal Neurological Inventory (NNI)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Neurobiological Risk Score (NBRS)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Gestational Age Factor (GAF) and Auditory Evoked Response Factor (AERF)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intraventricular Haemorrhage (IVH) and Bilirubin levels
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intraventricular Haemorrhage (IVH) and Assisted Ventilation
Number of subjects: 106
Study: 8076871

Group type: EXPERIMENTAL
Intervention: Clinical pharmacists' consultations
Number of subjects: 706

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 706
Study: 2644876

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 28
Study: 1155918

Group type: EXPERIMENTAL
Intervention: Sisomicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin (2 mg/kg)
Number of subjects: 0
Study: 31787410

Group type: EXPERIMENTAL
Intervention: Conspicuous messaging (highlighting the amount of rewards)
Number of subjects: 50286

Group type: EXPERIMENTAL
Intervention: Generic messaging (promoting vaccinations with no mention of rewards)
Number of subjects: 50286

Group type: COMPARATOR
Intervention: No-message control
Number of subjects: 50286
Study: 30205184

Group type: EXPERIMENTAL
Intervention: Integrated personalized diabetes management (iPDM)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 907
Study: 28683960

Group type: EXPERIMENTAL
Intervention: Sodium nitrite
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 26265109

Group type: EXPERIMENTAL
Intervention: Warming blanket plus prewarmed intravenous (i.v.) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Only blanket (blanket group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blanket plus electric blanket (heating blanket group)
Number of subjects: 0
Study: 22841432

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine (EPI100)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 epinephrine (EPI200)
Number of subjects: 60
Study: 20189775

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg every 12h for 5 days
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Oseltamivir 225 mg every 12h for 5 days
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Oseltamivir 450 mg every 12h for 5 days
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 20054189

Group type: EXPERIMENTAL
Intervention: Calcium carbonate and 1‐(OH)‐vitamin D supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 40
Study: 16844725

Group type: EXPERIMENTAL
Intervention: Speech pathology intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 87
Study: 12950861

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 6% (HES 70/0.5)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 64
Study: 10812285

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: THC (7.5 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: THC (15 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Naltrexone (0 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: THC (0 mg)
Number of subjects: 14
Study: 8684686

Group type: EXPERIMENTAL
Intervention: r-HuEPO (4000 IU/ml, subcutaneous treatment on alternate days)
Number of subjects: 24
Study: 1904892

Group type: EXPERIMENTAL
Intervention: Open label drug titration (nonrandomized patients)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Double-blind placebo therapy (control group)
Number of subjects: 318
Study: 6352602

Group type: EXPERIMENTAL
Intervention: Azlocillin plus tobramycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azlocillin plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticarcillin plus tobramycin
Number of subjects: 0
Study: 30738645

Group type: EXPERIMENTAL
Intervention: Intervention group (campaign on influenza vaccination)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 29171848

Group type: EXPERIMENTAL
Intervention: (+)-epicatechin (30 mg per day for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (+)-epicatechin (incremental doses of 10, 30 or 100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (+)-epicatechin (0.003, 0.01, 0.03, 0.1 and 0.3 mg kg-1 day-1 for 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: +catechin (0.1 mg kg-1 day-1)
Number of subjects: 0
Study: 29231495

Group type: EXPERIMENTAL
Intervention: Acupuncture (empirical ten needles, thirteen needles of the governor vessel, twelve needles of hand and foot, and symptomatic points)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Shallow needling therapy (at sites 0.2 to 0.3 cun lateral to the acupoints, no qi arrival required)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Shallow needling therapy
Number of subjects: 42
Study: 25588685

Group type: EXPERIMENTAL
Intervention: Ablation effectiveness quotient (AEQ) calculated from post-AFA levels of serum high sensitivity cardiac troponin T (HScTnT) and duration of RF application
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AEQ >0.4 ng/L/s in patients with paroxysmal AF
Number of subjects: 60
Study: 23218907

Group type: EXPERIMENTAL
Intervention: Simulation education
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Traditional classroom teaching + Simulation education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional classroom teaching
Number of subjects: 60
Study: 20081548

Group type: EXPERIMENTAL
Intervention: Preoperative fluid minihysteroscopy with low pressure saline uterine distention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no preoperative hysteroscopy)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study: 18160551

Group type: EXPERIMENTAL
Intervention: Electrical stimulation-assisted training
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electrical stimulation-unassisted training
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electrical stimulation training
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5
Study: 16636540

Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP >162.2 pmol/l
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP levels in the highest quartile (> or =162.2 pmol/l)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP
Number of subjects: 219
Study: 12559795

Group type: EXPERIMENTAL
Intervention: IM high dose hepatitis B virus (HBV) vaccine
Number of subjects: 60

Group type: COMPARATOR
Intervention: IM standard dose HBV vaccine plus granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard dose HBV vaccine plus GM‐CSF
Number of subjects: 60
Study: 10800019

Group type: EXPERIMENTAL
Intervention: Graded exercise program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 8987040

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 ug/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alfentanil 20 ug/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 45
Study: 8427660

Group type: COMPARATOR
Intervention: Magnesium supplementation (15 mmol Mg2+/day for 3 weeks, followed by 30 mmol Mg2+/day for another 3 weeks, finishing with 40 mmol Mg2+/day for a final 3 weeks)
Number of subjects: 17
Study: 3318723

Group type: EXPERIMENTAL
Intervention: 100 mg methylprednisolone infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 g methylprednisolone infusion
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (unspecified alternative therapy)
Number of subjects: 21
Study: 30665819

Group type: EXPERIMENTAL
Intervention: Opportunistic screening for low thoracic bone mineral density (BMD) using quantitative CT (QCT) software
Number of subjects: 1487
Study: 29059108

Group type: EXPERIMENTAL
Intervention: NMES + STSTS
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: STSTS only
Number of subjects: 63

Group type: COMPARATOR
Intervention: NAT
Number of subjects: 63
Study: 26153378

Group type: EXPERIMENTAL
Intervention: Isotonic saline irrigation after myringotomy
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin three times a day for 7 days postoperatively
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin plus topical ciprofloxacin drops (4 drops three times a day for 3 days)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 536
Study: 24856575

Group type: EXPERIMENTAL
Intervention: Oblique supine lithotomy position
Number of subjects: 203

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 203
Study: 24501360

Group type: EXPERIMENTAL
Intervention: Active location recall
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive dragging of objects to predetermined locations
Number of subjects: 0
Study: 21630376

Group type: EXPERIMENTAL
Intervention: Univalent stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bivalent stimuli
Number of subjects: 0
Study: 21199306

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Sanyinjiao (SP6)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at GB39
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at non-meridian point
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 52
Study: 17438709

Group type: EXPERIMENTAL
Intervention: Physical training (Phys)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Information (Info)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Physical training plus information (PhysInfo)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Standard care (C)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Physical Function (PF)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Role Function (RF)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Fatigue (FA)
Number of subjects: 211
Study: 16130647

Group type: EXPERIMENTAL
Intervention: Australian Orthotics Laboratory, three-quarter-length, flexible, shoe inserts
Number of subjects: 47

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 47
Study: 11854123

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 173
Study: 10419910

Group type: EXPERIMENTAL
Intervention: Outreach educational seminar combined with on-site sigmoidoscopy services
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 9
Study: 8843936

Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminders
Number of subjects: 213

Group type: COMPARATOR
Intervention: No reminders (control group)
Number of subjects: 213
Study: 1611835

Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg day‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6365809

Group type: EXPERIMENTAL
Intervention: sfericase (2 tablets, 3 times/day, total daily dose of 6 tablets)
Number of subjects: 109
Study: 29332024

Group type: EXPERIMENTAL
Intervention: Apotel (1 g in 200 cc normal saline for 20 min)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Remifentanil (0.5 μg/kg/min)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Narcotic use
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate
Number of subjects: 70
Study: 29378040

Group type: EXPERIMENTAL
Intervention: Breakfast Group (≥700 kcal before 1100)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting Group (0 kcal until 1200)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Breakfast Group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting Group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 27236292

Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23480201

Group type: EXPERIMENTAL
Intervention: Motivational-behavioural skills protocol for plaque control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic oral hygiene instruction (Control)
Number of subjects: 60
Study: 21829216

Group type: EXPERIMENTAL
Intervention: 7-day pre-coded food record (PFR) in 9-month-old infants
Number of subjects: 72

Group type: COMPARATOR
Intervention: 7-day weighed food record (WFR) in 9-month-old infants
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 7-day pre-coded food record (PFR) in 36-month-old children
Number of subjects: 72

Group type: COMPARATOR
Intervention: 7-day weighed food record (WFR) in 36-month-old children
Number of subjects: 72
Study: 20640546

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Power Training (PT) and Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study: 17324827

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 136

Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 136
Study: 16286743

Group type: EXPERIMENTAL
Intervention: Lichtena plus 25 microg/g triamcinolone acetonide (TACA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plain Lichtena (placebo)
Number of subjects: 14
Study: 11898768

Group type: EXPERIMENTAL
Intervention: Vitamins C and E (200mg vitamin C and 50mg vitamin E, both twice per day for 4 weeks)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Triple therapy (Bismuth chelate, tetracycline, and metronidazole for 2 weeks)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both treatments (Vitamins C and E + Triple therapy)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal controls (n=61)
Number of subjects: 117
Study: 10211862

Group type: EXPERIMENTAL
Intervention: NordicTrack (NT) cross‐country ski simulator
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treadmill (TM) test utilizing the Bruce protocol
Number of subjects: 28
Study: 7599850

Group type: EXPERIMENTAL
Intervention: Methacholine (0.03 to 256 mg/ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hypertonic saline (0.9 to 14.4% NaCl)
Number of subjects: 12
Study: 1450684

Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant vaccine 1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant vaccine 2
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine
Number of subjects: 3
Study: 6364880

Group type: EXPERIMENTAL
Intervention: alcohol/onion extract (5% ethanol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: control (5% ethanol solution)
Number of subjects: 12
Study: 31436165

Group type: EXPERIMENTAL
Intervention: mMitra, a stage-based voice messaging program
Number of subjects: 0
Study: 29396000

Group type: EXPERIMENTAL
Intervention: Cycling of antibiotics (third-generation or fourth-generation cephalosporins, piperacillin-tazobactam, and carbapenems)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Mixing strategy (changing antibiotic to an alternative class for each consecutive patient)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: All-cause in-ICU mortality
Number of subjects: 745
Study: 27273879

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) - 30 kcal/kg/day, 0.16 gN/kg/day for 12 hours prior to operation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline infusion for 12 hours prior to operation
Number of subjects: 22
Study: 24751304

Group type: EXPERIMENTAL
Intervention: Benzodiazepine users (at baseline or during follow-up)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Benzodiazepine non-users
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Patients who initiated benzodiazepines during follow-up
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Patients with comorbid anxiety or substance use disorders
Number of subjects: 482
Study: 21863458

Group type: EXPERIMENTAL
Intervention: Centre of Pressure (CoP) measurements
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Baseline and 12-week follow-up CoP measurements
Number of subjects: 97
Study: 20703197

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER) tablets, 3-15 mg/day (9 mg starting dose)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Paliperidone extended-release (ER) tablets
Number of subjects: 235
Study: 17113683

Group type: EXPERIMENTAL
Intervention: Tramadol/acetaminophen 75 mg/650 mg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen 7.5 mg/650 mg
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 16292444

Group type: EXPERIMENTAL
Intervention: Pro Root MTA (Dentsply) with 2% methylene blue solution
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Zinc oxide-eugenol cement (ZOE) with 2% methylene blue solution
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Pro Root MTA (Dentsply) with 0.2% rhodamine B
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Zinc oxide-eugenol cement (ZOE) with 0.2% rhodamine B
Number of subjects: 56
Study: 12111134

Group type: EXPERIMENTAL
Intervention: (131)I‐Lipiodol combined with low-dose cisplatin (30 mg/m2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: (131)I‐Lipiodol therapy alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (131)I‐Lipiodol combined with low-dose cisplatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cisplatin administration
Number of subjects: 20
Study: 10536065

Group type: EXPERIMENTAL
Intervention: Nested PCR
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Mycobacterial cultures
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Smears
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (children without active disease)
Number of subjects: 117
Study: 7892259

Group type: EXPERIMENTAL
Intervention: Anti-platelet IgG
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PEG-ICs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: F(ab')2 fragments of anti-platelet IgG
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Scatchard analysis
Number of subjects: 27
Study: 1977779

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Not taking beta-blocker
Number of subjects: 1084
Study: 326380

Group type: EXPERIMENTAL
Intervention: Conservative procedure (mammary resection plus axillary dissection plus radiotherapy)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 331
Study: 31469710

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation after eccentric exercise‐induced muscle damage (DEPRIVATION)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regular sleep after eccentric exercise‐induced muscle damage (SLEEP)
Number of subjects: 10
Study: 31554878

Group type: EXPERIMENTAL
Intervention: Simultaneous cardiac and lung CT (Gr.A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard cardiac CT only (Gr.B)
Number of subjects: 110
Study: 27584910

Group type: EXPERIMENTAL
Intervention: Decision aid for breast cancer prevention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 150
Study: 25640536

Group type: EXPERIMENTAL
Intervention: Gas, dust, and fumes (GDF) exposure
Number of subjects: 788
Study: 23070934

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Community caregiver education and support (CCES)
Number of subjects: 78
Study: 20690865

Group type: EXPERIMENTAL
Intervention: Tibolone (daily tablet for 6 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no hormone therapy)
Number of subjects: 60
Study: 19075260

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 16420289

Group type: EXPERIMENTAL
Intervention: NG ‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15313671

Group type: EXPERIMENTAL
Intervention: Peg-IFN alpha-2a (pegasys)
Number of subjects: 202

Group type: COMPARATOR
Intervention: IFN-alpha-2a (roferon-A)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Genotype 1 HCV
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Genotype non-1 HCV
Number of subjects: 202

Group type: COMPARATOR
Intervention: Genotype 1 HCV in roferon-A group
Number of subjects: 202

Group type: COMPARATOR
Intervention: Genotype non-1 HCV in roferon-A group
Number of subjects: 202
Study: 11352878

Group type: EXPERIMENTAL
Intervention: Abciximab (n=13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 23
Study: 9413962

Group type: EXPERIMENTAL
Intervention: Hepatic arterial resistance index (HARI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Liver function tests (SGOT, SGPT, ALK, LDH, ALB)
Number of subjects: 31
Study: 8280821

Group type: EXPERIMENTAL
Intervention: sucralfate gel (Gastrogel)
Number of subjects: 25

Group type: COMPARATOR
Intervention: sucralfate suspension
Number of subjects: 25
Study: 3449067

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of piretanide (6 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous administration of piretanide (6 mg)
Number of subjects: 10
Study: 29635492

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation (400 µg/d)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 27490103

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (2 capsules of 20 mg per day) and placebo of vitamin D (P+S)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU biweekly) and placebo of soy isoflavones (D+P)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Soy isoflavones and Vitamin D (D+S)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo of vitamin D and placebo of soy isoflavones (P+P)
Number of subjects: 100